Clearstead Trust LLC Buys New Shares in IQVIA Holdings Inc. $IQV

Clearstead Trust LLC bought a new position in shares of IQVIA Holdings Inc. (NYSE:IQV) during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor bought 3,888 shares of the medical research company’s stock, valued at approximately $751,000.

A number of other hedge funds have also recently bought and sold shares of the stock. Ascentis Independent Advisors bought a new stake in shares of IQVIA during the 1st quarter worth approximately $25,000. Financial Freedom LLC bought a new position in shares of IQVIA in the first quarter valued at $25,000. International Assets Investment Management LLC acquired a new position in IQVIA during the fourth quarter worth $27,000. Gilpin Wealth Management LLC acquired a new position in IQVIA during the fourth quarter worth $27,000. Finally, CrossGen Wealth LLC bought a new stake in IQVIA during the fourth quarter worth $28,000. 89.62% of the stock is currently owned by institutional investors.

Insider Activity at IQVIA

In other news, insider Eric Sherbet sold 5,000 shares of the stock in a transaction that occurred on Wednesday, July 29th. The stock was sold at an average price of $249.16, for a total transaction of $1,245,800.00. Following the transaction, the insider owned 20,999 shares in the company, valued at approximately $5,232,110.84. This trade represents a 19.23% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Keriann Cherofsky sold 558 shares of IQVIA stock in a transaction that occurred on Wednesday, July 29th. The stock was sold at an average price of $245.21, for a total value of $136,827.18. Following the sale, the insider directly owned 2,989 shares of the company’s stock, valued at approximately $732,932.69. The trade was a 15.73% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 12,913 shares of company stock valued at $3,098,793 in the last 90 days. Insiders own 1.70% of the company’s stock.

IQVIA Trading Down 2.2%

IQV stock opened at $236.18 on Friday. IQVIA Holdings Inc. has a one year low of $154.50 and a one year high of $251.36. The stock has a market cap of $38.87 billion, a price-to-earnings ratio of 29.30, a price-to-earnings-growth ratio of 2.01 and a beta of 1.18. The company has a fifty day moving average price of $206.65 and a two-hundred day moving average price of $187.09. The company has a debt-to-equity ratio of 2.18, a current ratio of 0.71 and a quick ratio of 0.71.

IQVIA (NYSE:IQV) last issued its quarterly earnings data on Tuesday, July 28th. The medical research company reported $3.15 earnings per share for the quarter, beating the consensus estimate of $3.03 by $0.12. The company had revenue of $4.37 billion for the quarter, compared to analyst estimates of $4.30 billion. IQVIA had a net margin of 8.10% and a return on equity of 30.25%. The company’s revenue was up 8.7% on a year-over-year basis. During the same period in the prior year, the firm earned $2.81 earnings per share. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. Equities analysts anticipate that IQVIA Holdings Inc. will post 11.57 EPS for the current year.

IQVIA announced that its board has authorized a share buyback program on Thursday, May 7th that permits the company to buyback $2.00 billion in shares. This buyback authorization permits the medical research company to reacquire up to 6.8% of its shares through open market purchases. Shares buyback programs are typically a sign that the company’s board believes its shares are undervalued.

Analyst Ratings Changes

A number of brokerages have recently commented on IQV. Morgan Stanley reissued an “equal weight” rating and issued a $200.00 price objective (down from $225.00) on shares of IQVIA in a research report on Wednesday, June 17th. Mizuho upped their target price on shares of IQVIA from $215.00 to $230.00 and gave the company an “outperform” rating in a report on Monday, July 13th. Weiss Ratings upgraded shares of IQVIA from a “hold (c-)” rating to a “hold (c)” rating in a research note on Wednesday, July 15th. Stifel Nicolaus lifted their price target on IQVIA from $220.00 to $276.00 and gave the stock a “buy” rating in a report on Wednesday, July 29th. Finally, William Blair raised IQVIA to a “strong-buy” rating in a research report on Tuesday, July 28th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $241.88.

About IQVIA

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.